Compositions and methods comprising splicing-derived antigens for treating cancer
AssigneeThe Regents of the University of California
InventorsYi XING, Owen WITTE, John PHILLIPS, Yang PAN
Life of this patent
Estimating the term…
Abstract
Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.
Claims22
A peptide comprising at least 70% sequence identity to a peptide of SEQ ID NO:1-19.
A peptide comprising at least 6 contiguous amino acids from an alternatively spliced polypeptide,
- wherein the at least 6 contiguous amino acids comprises an alternative splice site junction of the polypeptide or wherein the peptide comprises at least 6 contiguous amino acids from an alternatively spliced exon;
- and
- wherein the alternatively spliced peptide, exon, or junction is one that is derived from an alternative splice event (AS event) identified in Table 1a, 1b, 1c, or 1d.
20-21. (canceled)
23-137. (canceled)
Dependencies are inferred from the claim text.